NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that CDX-1127, a preclinical therapeutic antibody program for oncology indications, is the subject of a poster presentation at the 2010 American Association for Cancer Research (AACR) 101st Annual Meeting in Washington DC. The presentation (poster #5343) is entitled “Development of Novel Anti-CD27 Human Antibodies with Therapeutic Potential”, and describes preclinical in vitro and animal data with candidate antibodies for clinical development. The presentation is scheduled from 8:00 a.m. to 11:00 a.m. EDT today in Exhibit Hall A-C at the Walter E. Washington Convention Center.
